Regeneron Pharmaceuticals’ combo therapy containing its flagship eye drug, Eylea, was inferior to Eylea alone in a mid-stage trial involving patients with wet AMD.

Amgen’s multiple myeloma drug did not fare better than Takeda’s older therapy Velcade in a study involving patients who had not yet been treated for the disease.

Johnson & Johnson said the U.S. Food and Drug Administration approved the company’s blockbuster psoriasis drug Stelara for adults with Crohn’s disease.

Novartis’ Zykadia drug performed well against a rare form of lung cancer, citing a study the Swiss company hopes will help it win expanded regulatory approval.

The U.S. FDA approved a pill that combines aspirin and the acid-fighting drug omeprazole to guard against gastric ulcers in patients who require daily aspirin.

Takeda announced the launch of an Access to Medicines (AtM) strategy aimed at increasing access to its innovative and potentially life-saving medicines.

Recent clinical trial results are likely to lead doctors to treat more patients who have a common form of lung cancer with a Merck drug at the expense of a Bristol-Myers Squibb medication at least until more data emerges, oncologists and analysts say.

Mylan NV said it would reduce the out-of-pocket cost of its severe allergy treatment EpiPen through a discount program after lawmakers criticized the drug’s high price.

The U.S., which spends more on drugs than any other country, might contain costs by limiting market exclusivity for brand name medicines and changing coverage requirements for government health plans, some doctors argue.

AbbVie’s biologic therapy Humira for autoimmune diseases was the worldwide prescription-drug sales leader in 2015 for the fourth consecutive calendar term.